Lise Lund Kjems
Keine laufenden Positionen mehr
Vermögen: 21 828 $ am 31.05.2024
Karriereverlauf von Lise Lund Kjems
Ehemalige bekannte Positionen von Lise Lund Kjems
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CYCLO THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.09.2021 | 01.04.2023 |
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | - | - |
Ausbildung von Lise Lund Kjems
| University of Copenhagen | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Dänemark | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CYCLO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Lise Lund Kjems
- Erfahrung
